PT  - JOURNAL ARTICLE
AU  - Sahu, Sukanya
AU  - Kaushik, Sandeep R.
AU  - Chaudhary, Shweta
AU  - Mahapatra, Amit kumar
AU  - Kappa, Rukuwe
AU  - Kapfo, Wetesho
AU  - Saha, Sourav
AU  - Das, Ranjit
AU  - Das, Anjan
AU  - Khamo, Vinotsole
AU  - Nanda, Ranjan Kumar
TI  - Gut microbiota dysbiosis observed in tuberculosis patients resolves partially with anti-tuberculosis therapy
AID  - 10.1101/2023.06.14.23291387
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.06.14.23291387
4099  - http://medrxiv.org/content/early/2023/06/15/2023.06.14.23291387.short
4100  - http://medrxiv.org/content/early/2023/06/15/2023.06.14.23291387.full
AB  - Objective Mycobacterium tuberculosis (Mtb) primarily affects the lungs with involvement of other organs causing tuberculosis (TB) in humans. Since the lung-gut axis is bidirectional, and the gut microbiota contributes to metabolic and immune homeostasis, we looked at the gut microbiota and metabolites of TB patients and controls, and whether the perturbations, if any, resolve with anti-tuberculosis treatment.Methods In this multicentric case-control study, a total of 107 fecal samples belonging to drug naïve active tuberculosis (ATB) patients and controls (non-tuberculosis: NTB and healthy), were collected from two clinical sites in India. A group of drug-naïve ATB patients (n=10) from one site was followed-up and monitored at 2, 4, 6, and 8 months of their anti-tuberculosis treatment. The fecal microbiome and metabolome of these study participants were characterized by 300 bp pair end sequencing of the V3-V4 region of 16S rRNA gene and gas chromatography-time of flight-mass spectrometry (GC-TOF-MS) respectively to identify disease and treatment-specific variations, if any.Results Drug naïve ATB and NTB patients showed a significant reduction of gut microbial diversity with respect to age matched healthy controls in both the clinical sites. ATB patient’s had underrepresentation of gut commensals such as Faecalibacterium prausnitzii, Prevotella copri DSM 18205, Coprococcus catus, and overrepresentation of Clostridium difficile ATCC 9689 = DSM 1296. Longitudinally followed-up ATB patients showed elimination of Alkalihalobacillus with treatment initiation, whereas harmful taxa such as Stenotrophomonas and Klebsiella pneumoniae appeared in treatment-completed subjects. Interestingly, the fecal metabolites also showed group-specific differences, clustering ATB patients away from the controls irrespective of the study sites. Consistently, fecal 2-piperidinone abundance was higher in ATB patients compared to healthy controls. The fecal metabolome of longitudinally followed-up ATB patients showed a gradual shift towards healthy during the course of treatment completion.Conclusion Gut microbial dysbiosis observed in tuberculosis patients at case presentation is partially resolved with 6 months of treatment completion and also reflected in their metabolite level. The observed microbial and metabolite imbalance in these ATB patients could explain disease pathology which needs further exploration to exploit their translational potential for therapeutics development.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partly supported by the NER grant to RKN, AD and VK from Department of Biotechnology New Delhi. CORE support of ICGEB to RKN is acknowledged. SS, SRK, SS received fellowships from Council of Scientific and Industrial Research, New Delhi.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the institute review boards of Naga Hospital Authority, Kohima (NHAK) (NHAK/HLRC-008/2012 dated 17th May 2017); Agartala Government Medical College, Agartala (AGMC) (protocolF.4[6-9]/AGMC/Academic/IEC Committee/2015/8965, dated 25 April 2018), and International Centre for Genetic Engineering and Biotechnology, New Delhi (ICGEB/IEC/2017/07). Written informed consent was obtained from all participants prior to collecting biological samples.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced are available online at https://www.ncbi.nlm.nih.gov/bioproject/PRJNA972267https://www.ncbi.nlm.nih.gov/bioproject/PRJNA972267